RegCell closed a $66 million funding round to advance its immune tolerance platform built on regulatory T cells, combining a fully subscribed $44 million Series A with a $22 million non-dilutive grant from Japan’s AMED. The round is designed to move its Nobel-winning Treg approach closer to clinical application. The funding supports further development and translational work, including the pathway from platform generation into therapeutics appropriate for early clinical testing. RegCell’s approach aligns with growing investor appetite for cell and immune tolerance modalities that aim to treat disease by resetting immune regulation. For clinicians and developers, the financing indicates continued backing for next-generation Treg companies that can demonstrate manufacturability, safety, and consistent functional performance across patient populations.